ArticleOrganogenesis2026
Optimization of TX-100/SDS-based decellularized vascular material using ultrasound and chemical treatment: evaluation of structure and biosafety.
Article in Organogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decellularized blood vessels with low immunogenicity and excellent biocompatibility are promising for tissue engineering and clinical applications. However, current decellularization methods face limitations in cell removal efficiency, matrix preservation, and biosafety. This study optimized the Triton X-100/SDS (TX-100/SDS) decellularization method using ultrasound technology by systematically evaluating the effects of ultrasound power, temperature, and processing time on decellularization efficiency. The optimized method achieved a 72% reduction in nucleic acid residues at 100 W power while preserving matrix integrity and significantly reducing chemical reagent residues. Structural and biosafety evaluations confirmed that the optimized scaffolds met biological safety standards and demonstrated excellent stability, providing a strong foundation for developing high-performance decellularized vascular materials for clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.